Komori
Tsubota Laboratory (4890) · InitiativeAdvanced

Development and Out-Licensing of TLM-018, a Novel Ophthalmic Drug

First written in FY2024. 2 of 5 entries say "Achieved", first in 2026-03-26. Latest entry: FY2026.

5entries
3years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024Achieved2026-03-26 – FY20262024: 120242025: 020252026: 42026
Same theme, other companies
Development, out-licensing and launch of the novel TLM-018 ophthalmic drugA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「March 2026　Product related to the company's TLM-018 pipeline launched by Rohto Pharmaceutical Co., Ltd.」

    TLM-018 progressed from the stage of entering into a licensing agreement with Rohto Pharmaceutical and beginning development to the stage of launching a related product.
  3. FY2024First statedAnnual report

    「The company entered into an intellectual property licensing agreement with Rohto Pharmaceutical Co., Ltd. and began development of a new ophthalmic drug, TLM-018.」

    The company has for the first time disclosed the start of TLM-018 development under the intellectual property licensing agreement with Rohto Pharmaceutical.
Moved together

"Global Out-Licensing and Royalty Monetization of TLM-001, a Treatment for Meibomian Gland Dysfunction" moved the same way as this thread, in the same document, in 3 of its 5 moves.

333333★123456
  1. ★This thread
  2. 1Global Out-Licensing and Royalty Monetization of TLM-001, a Treatment for Meibomian Gland Dysfunction3×
  3. 2Commercialization of R&D Pipelines and Establishment of Post-Launch Royalty Revenue3×
  4. 3Strengthening basic research3×
  5. 4Clinical Trial and Launch of TLM-003 Myopia Progression Prevention Eye Drops3×
  6. 5Development of an innovative medical device for retinitis pigmentosa3×
  7. 6Creating new revenue opportunities by expanding into the cosmetics business3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Tsubota Laboratory yet. It last moved in the Financial Results Presentation of 2026-05-14: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Development and Out-Licensing of TLM-018, a Novel Ophthalmic Drug | Tsubota Laboratory Incorporated (4890) | Komori